Announcement • Jun 30
Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced Platform Enhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform. Announcement • Jun 15
Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group Limited Enhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors. 
